Similar articles for PMID: 18221614

Year	Number of Results
2000	1
2001	5
2002	4
2003	16
2004	16
2005	12
2006	9
2007	6
2008	6
2009	8
2010	8
2011	7
2012	8
2013	9
2014	10
2015	3
2016	1
2017	2
2018	2
2019	1
2020	1
2021	11
2022	12
2023	1
2024	0

1

Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.

Verma A, Solomon SD. Verma A, et al. Curr Heart Fail Rep. 2007 Dec;4(4):183-9. doi: 10.1007/s11897-007-0011-8. Curr Heart Fail Rep. 2007. PMID: 18221614 Review.

2

[Aldosterone receptor blockade after acute myocardial infarction with heart failure].

Bauersachs J, Ertl G. Bauersachs J, et al. Med Klin (Munich). 2006 Jun 15;101(6):458-66. doi: 10.1007/s00063-006-1063-3. Med Klin (Munich). 2006. PMID: 16767569 Review. German.

3

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.

McKenna C, Burch J, Suekarran S, Walker S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Lorgelly P, Fenwick L, Palmer S. McKenna C, et al. Health Technol Assess. 2010 May;14(24):1-162. doi: 10.3310/hta14240. Health Technol Assess. 2010. PMID: 20492762 Free article. Review.

4

Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.

Keating GM, Plosker GL. Keating GM, et al. Drugs. 2004;64(23):2689-707. doi: 10.2165/00003495-200464230-00005. Drugs. 2004. PMID: 15537370 Review.

5

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Pitt B, et al. N Engl J Med. 2003 Apr 3;348(14):1309-21. doi: 10.1056/NEJMoa030207. Epub 2003 Mar 31. N Engl J Med. 2003. PMID: 12668699 Free article. Clinical Trial.

6

The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.

Davis KL, Nappi JM. Davis KL, et al. Clin Ther. 2003 Nov;25(11):2647-68. doi: 10.1016/s0149-2918(03)80326-0. Clin Ther. 2003. PMID: 14693297 Review.

7

Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.

O'Keefe JH, Abuissa H, Pitt B. O'Keefe JH, et al. Diabetes Obes Metab. 2008 Jun;10(6):492-7. doi: 10.1111/j.1463-1326.2007.00730.x. Epub 2007 May 8. Diabetes Obes Metab. 2008. PMID: 17490427

8

Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.

Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, Vincent J, Pitt B, Zannad F. Iraqi W, et al. Circulation. 2009 May 12;119(18):2471-9. doi: 10.1161/CIRCULATIONAHA.108.809194. Epub 2009 Apr 27. Circulation. 2009. PMID: 19398668 Clinical Trial.

9

Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).

Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R; EPHESUS Investigators. Pitt B, et al. Circulation. 2008 Oct 14;118(16):1643-50. doi: 10.1161/CIRCULATIONAHA.108.778811. Epub 2008 Sep 29. Circulation. 2008. PMID: 18824643 Clinical Trial.

10

New treatment option for heart failure patients: eplerenone.

Southworth MR, Cavallari LH. Southworth MR, et al. J Cardiovasc Nurs. 2004 Nov-Dec;19(6):390-5. doi: 10.1097/00005082-200411000-00010. J Cardiovasc Nurs. 2004. PMID: 15529060 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

144 results

Results by year